Overview

• Acurx Q3 net loss narrows to $2 mln, with EPS at -$1.23

• R&D expenses decreased to $0.4 mln due to lower manufacturing and consulting costs

• Company completed 1-for-20 reverse stock split, regaining Nasdaq compliance

Result Drivers

• REVERSE STOCK SPLIT - Co completed a 1-for-20 reverse stock split, regaining Nasdaq compliance

• R&D EXPENSES - R&D expenses decreased due to lower manufacturing and consulting costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $30.50, about 81.7% above its November 11 closing price of $5.58

Press Release: ID:nPn9b8nGla

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)